Skip to content
MARKETS / NASDAQ / ABEO
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Abeona Therapeutics Inc. ABEO

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.8M
$71.2M
$-84.3M
In brief

What this company does

ZEVASKYN® is manufactured at our current Good Manufacturing Practices (“cGMP”) manufacturing facility in Cleveland, Ohio. As of March 2026, we have activated 4 qualified treatment centers and are in discussions with additional centers as we continue to expand the ZEVASKYN® qualified treatment network. The Company’s development portfolio also features adeno-associated virus (“AAV”)-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids.

Written from the business description in Abeona Therapeutics Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 March 2026. Every sentence was checked against that document before publication.

Growth
USD 5.8M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.8 · Net income 71.2
25.0M50.0M-40.0M-80.0M201020122014201620182020202220242025
Compound annual growth
+60.3%
−10.3%
+18.8%
+18.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −10.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
1223 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -1536.9% · Net 1223.1%
500%1000%-1000%-2000%-3000%201020122014201620182020202220242025
ROE
FY2025 · ROE 70.0%
20%40%60%-100%-200%201020122014201620182020202220242025

Each USD of equity produced 70 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -84.3
-40M-80M201020122014201620182020202220242025

Total assetsUSD 219.6M
EquityUSD 159.2M
CashUSD 78.4M
Gross debtUSD 20.0M
Net debtUSD -58.4M
Current ratio6.93×

The company holds more cash than debt.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.0·0.00.00.00.0·0.00.00.00.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0······0.00.00.00.00.00.00.00.00.0
Net income $B0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.0−0.0−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $1.01−1.55−2.53−5.53−0.86−0.91−1.51−1.19−0.66−0.64−0.53−15.263.04−0.52−0.22−0.60
Dividend / sh $················
Payout %················
ROE %70.0−216.6−260.6−114.8−117.2−60.0−48.8−37.3−20.3−26.2−40.1·····
Shares out B0.060.050.030.020.010.100.080.050.050.04······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 63 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 26 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image